Biotech Values

[DewDiligence]

AVNR—[NYT article is] misleading because it didn't clearly state what the drug is approved for…

I may be nitpicking here, but the FDA label for Nuedexta does not explicitly restrict use to patients with MS/ALS; rather, the label merely states that the studies supporting approval were conducted in patients with MS/ALS.

From a reimbursement standpoint, the above distinction may not matter; however, I think you were unduly critical of the NYT article in #msg-56108000 when you accused it of misstating the approved indication.